Suppr超能文献

预后标志物的报告:当前问题及未来循证实践指南的制定。

Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future.

作者信息

Riley R D, Abrams K R, Sutton A J, Lambert P C, Jones D R, Heney D, Burchill S A

机构信息

Department of Epidemiology and Public Health, University of Leicester, Leicester, UK.

出版信息

Br J Cancer. 2003 Apr 22;88(8):1191-8. doi: 10.1038/sj.bjc.6600886.

Abstract

Prognostic markers help to stratify patients for treatment by identifying patients with different risks of outcome (e.g. recurrence of disease), and are important tools in the management of cancer and many other diseases. Systematic review and meta-analytical approaches to identifying the most valuable prognostic markers are needed because (sometimes conflicting) evidence relating to markers is often published across a number of studies. To investigate the practicality of this approach, an empirical investigation of a systematic review of tumour markers for neuroblastoma was performed; 260 studies of prognostic markers were identified, which considered 130 different markers. The reporting of these studies was often inadequate, in terms of both statistical analysis and presentation, and there was considerable heterogeneity for many important clinical/statistical factors. These problems restricted both the extraction of data and the meta-analysis of results from the primary studies, limiting feasibility of the evidence-based approach.Guidelines for reporting the results of primary prognostic marker studies in cancer, and other diseases, are given in order to facilitate both the interpretation of individual studies and the undertaking of systematic reviews, meta-analysis and, ultimately, evidence-based practice. General availability of full individual patient data is a necessary step forward and would overcome the majority of problems encountered, including poorly reported summary statistics and variability in cutoff level, outcome assessed and adjustment factors used. It would also limit the problem of reporting bias, although publication bias will remain a concern until studies are prospectively registered. Such changes in practice would help important evidence-based reviews to be conducted in order to establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care.

摘要

预后标志物有助于通过识别具有不同预后风险(如疾病复发)的患者来对患者进行治疗分层,是癌症和许多其他疾病管理中的重要工具。由于有关标志物的证据(有时相互矛盾)通常在多项研究中发表,因此需要采用系统评价和荟萃分析方法来识别最有价值的预后标志物。为了研究这种方法的实用性,对神经母细胞瘤肿瘤标志物的系统评价进行了实证研究;共识别出260项关于预后标志物的研究,涉及130种不同的标志物。这些研究在统计分析和呈现方面的报告往往不充分,许多重要的临床/统计因素存在相当大的异质性。这些问题限制了数据提取和对原始研究结果的荟萃分析,限制了循证方法的可行性。给出了癌症及其他疾病中主要预后标志物研究结果的报告指南,以促进对个体研究的解读以及系统评价、荟萃分析的开展,并最终推动循证实践。全面获取个体患者完整数据是向前迈出的必要一步,将克服遇到的大多数问题,包括报告不充分的汇总统计数据以及截断水平、评估的结局和使用的调整因素的变异性。这也将限制报告偏倚问题,尽管在研究进行前瞻性注册之前,发表偏倚仍将是一个问题。这种实践上的改变将有助于开展重要的循证综述,以确定临床使用中最合适的预后标志物,最终改善患者护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3282/2747576/270bdf1becb3/88-6600886f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验